Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology's stock price has experienced significant movements in the past six months. The share price as of April 9, 2026, was $7.80, a substantial increase from $2.74 on April 10, 2025. Key events impacting the stock include Q4 2025 financial results and 2026 guidance, inclusion in the Nasdaq Biotechnology Index in December 2025, Q3 2025 financial results, presentations and conference calls, and inducement awards.

The provided information does not contain specific details regarding the demand seasonality for Puma Biotechnology's products and services. The nature of cancer treatment generally suggests a consistent demand for therapeutics rather than seasonal variations.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel cancer therapeutics. Their primary product is NERLYNX (neratinib) tablets, an oral kinase inhibitor approved for certain HER2-positive breast cancer treatments. The company is also developing alisertib for various cancers and has launched Phase II ALISCA trials.

Puma Biotechnology is headquartered in Los Angeles, California, and sells its products in the United States through specialty pharmacy and distributor networks. Internationally, NERLYNX is commercialized through license and sub-license agreements with partners in Europe, Africa, Greater China, Israel, Canada, South East Asia, and Latin America. NERLYNX became available in Thailand in December 2024.

Puma Biotechnology's brand reputation is centered around its mission to develop and commercialize innovative cancer therapeutics. The company's news flow consistently reflects its oncology focus, particularly concerning NERLYNX and alisertib. Inclusion in the Nasdaq Biotechnology Index is a positive indicator, while weaker-than-expected 2026 guidance primarily impacted investor sentiment.

Puma Biotechnology, Inc. has significant institutional ownership, with 154 institutional owners holding approximately 70.12% of the shares outstanding. Major institutional owners include Acorn Capital Advisors, Llc, Vanguard Group Inc, and BlackRock, Inc. Individual insider ownership stands at approximately 17.69%, with Alan H. Auerbach (Founder, Chairman, President, CEO & Secretary) holding 14.36% of the shares.